Table of Contents
Headline: Anixa Biosciences Reports Changes in Stock Option Grants and Stock-Based Consulting Expense
Anixa Biosciences, Inc. (ANIX) has recently released its quarterly report for the period ending April 30, 2023. The report highlights several key aspects of the company’s financials and operations, including changes in stock option grants and stock-based consulting expense.
Changes in Stock Option Grants
According to the report, during the three months ended April 30, 2023, Anixa Biosciences granted options to purchase 0 shares of common stock to employees and consultants. This is a decrease compared to the 1,400,000 shares of common stock granted in the same period in 2022. However, during the six months ended April 30, 2023, the company granted options to purchase 1,505,000 shares of common stock, which is an increase from the 1,430,000 shares granted in the same period in 2022.
Exercise Prices and Proceeds
The exercise prices for the granted options ranged from $4.19 to $4.81 per share. During the period, stock options to purchase 27,818 shares of common stock were exercised, resulting in aggregate proceeds of $75,000. This represents an increase from the previous year when no stock options were exercised.
Stock-Based Consulting Expense
Anixa Biosciences also recorded stock-based consulting expense related to stock options granted to consultants, amounting to approximately $47,000 for the three months ended April 30, 2023. This is a decrease from the $109,000 recorded in the same period in 2022. Additionally, stock-based consulting expense for the six months ended April 30, 2023, was approximately $128,000, compared to $218,000 in the same period in 2022.
Stock Option Plans
The report also provides information on the company’s stock option plans, including the Anixa Biosciences, Inc. 2010 Share Incentive Plan and the Anixa Biosciences, Inc. 2018 Share Incentive Plan. These plans allow for the grant of stock options, stock appreciation rights, stock awards, performance awards, and stock units to employees, directors, and consultants.
Overall, Anixa Biosciences’ quarterly report highlights changes in stock option grants and stock-based consulting expense during the three months ended April 30, 2023. These numbers reflect the company’s ongoing efforts to incentivize employees and consultants through stock-based compensation.
Note that we may hold securities mentioned in this article. All data is based on recent SEC filings. Even though we have implemented various manual and automatic fact-checking and data acquisition processes, some incorrect information may have slipped through (false positive). Let us know if you find any inconsistencies!